SAF
CNSP icon

Smith Anglin Financial’s CNS Pharmaceuticals CNSP Stock Holding History

Smith Anglin Financial’s Portfolio CNSP Stock Details CNSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-3
Closed -$32.7K – 200
2024
Q1 		$32.7K Buy
3
+1
+50% +$14.5K ﹤0.01% 197
2023
Q4 		$63.5K Buy
+2
New +$105K 0.01% 180

Other funds holding CNSP

AFM
Anson Funds Management Dallas, Texas $2.29B AUM 370.24% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
GRP
Global Retirement Partners San Rafael, California $5.64B AUM
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PA
Parallel Advisors San Francisco, California $5.56B AUM 17.89% 1-Year Est. Return
PMFA
Plante Moran Financial Advisors Southfield, Michigan $1.55B AUM 17.93% 1-Year Est. Return

Smith Anglin Financial's CNSP Position: Q2 2024 in Review

Smith Anglin Financial sold out of CNS Pharmaceuticals (CNSP) in Q2 2024, closing a stake of 3 shares — an estimated $32.7K sold.

Smith Anglin Financial first reported a position in CNSP in Q4 2023 and held it in 2 quarters. The position peaked at $63.5K in Q4 2023. 2 funds tracked by Wall St. Rank hold CNSP as of Q2 2024.

  • Smith Anglin Financial reported no remaining CNS Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • Smith Anglin Financial sold 3 CNS Pharmaceuticals shares in Q2 2024, an estimated $32.7K.
  • Smith Anglin Financial first reported a position in CNS Pharmaceuticals in Q4 2023 and held it in 2 quarters.
  • Smith Anglin Financial's CNS Pharmaceuticals position peaked at $63.5K in Q4 2023.
  • 2 funds tracked by Wall St. Rank held CNS Pharmaceuticals as of Q2 2024.

Based on Smith Anglin Financial's 13F filing for Q2 2024, filed 11 Jul 2024.